Effect of omega-3 fatty acid supplementation on diabetes mellitus patients

Effect of omega-3 fatty acid supplementation on homocysteine, lipid profile and insulin resistance in patients with diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013011312122N1

Enrollment

Registered

2013-01-29

Start date

2013-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Non-insulin dependent diabetes mellitus

Interventions

Intervention 1: omega-3, 1 gr soft gel, twice a day for 6 weeks. Intervention 2: placebo capsule containing inert Polyethylene glucose, 1 gr soft gel, twice a day for 6 weeks.

Treatment - Drugs

omega-3, 1 gr soft gel, twice a day for 6 weeks

placebo capsule containing inert Polyethylene glucose, 1 gr soft gel, twice a day for 6 weeks

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients with diagnosed diabetes and age of 25 to 60 years; a minimum of 5 years experience in diabetes; without any kidney; liver heart; thyroid, bleeding disorders or malignancies; not taking omega-3 supplements in recent months; not using insulin therapy; not pregnant or lactating. exclusion criteria: taking less than 80% of soft gels; changing the type and dose of routine medicine; consume B vitamins supplements during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum homocysteine. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic cycling using Reagent kit.;Fasting blood glucose. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;Fasting serum insulin. Timepoint: baseline and after 6 weeks. Method of measurement: ELISA assay.;Insulin resistance. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.;Beta cells function. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.;Serum Triglycerides. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;Total Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;HDL- Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;LDL-Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: Friedewald formula.;Insulin sensitivity. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.	—

Measure

Time frame

Serum homocysteine. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic cycling using Reagent kit.;Fasting blood glucose. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;Fasting serum insulin. Timepoint: baseline and after 6 weeks. Method of measurement: ELISA assay.;Insulin resistance. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.;Beta cells function. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.;Serum Triglycerides. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;Total Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;HDL- Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: enzymatic.;LDL-Cholesterol. Timepoint: baseline and after 6 weeks. Method of measurement: Friedewald formula.;Insulin sensitivity. Timepoint: baseline and after 6 weeks. Method of measurement: HOMA-IR calculation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaezeh Poursoleiman

Yazd Shahid Sadoughi University of Medical Sciences.

f.poursoleiman@ssu.ac.irf_po_yazd@yahoo.com+98 35 1623 4120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026